The metabolic syndrome and endothelial dysfunction: Common highway to type 2 diabetes and CVD?

被引：49

作者：

Diamant M. ^{[1
]}

Tushuizen M.E. ^{[1
]}

机构：

[1] Department of Endoncrinology, Diabetes Center, VU University Medical Center, 1007 MB Amsterdam

来源：

Current Diabetes Reports | 2006年 / 6卷 / 4期

关键词：

Insulin Resistance; Metabolic Syndrome; Metformin; Endothelial Dysfunction; Pioglitazone;

D O I：

10.1007/s11892-006-0061-4

中图分类号：

学科分类号：

摘要：

Due to global lifestyle changes, obesity (the main driver of type 2 diabetes [T2D] and cardiovascular disease [CVD]) is reaching pandemic proportions. The metabolic syndrome, which is regarded as a prediabetic state, is characterized by a concurrence of interrelated cardiovascular risk factors, including abdominal obesity, insulin resistance, hypertension, dyslipidemia, and glucose intolerance. Endothelial dysfunction (ED) is common in the metabolic syndrome and is associated with increased risk for T2D and CVD. This review focuses on the mechanisms linking ED to the metabolic syndrome, T2D, and CVD, and the possible therapies that may improve ED and reduce T2D and CVD risk. Copyright © 2006 by Current Science Inc.

引用

页码：279 / 286

页数：7

共 77 条

[1]

Yach D., Stuckler D., Brownell K.D., Epidemiologic and economic consequences of the global epidemics of obesity and diabetes, Nat Med, 12, pp. 62-66, (2006)

[2]

Roglic G., Unwin N., Bennett P.H., Et al., The burden of mortality attributable to diabetes: Realistic estimates for the year 2000, Diabetes Care, 28, pp. 2130-2135, (2005)

[3]

Hu F., Stampfer M.J., Haffner S.M., Et al., Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes, Diabetes Care, 25, pp. 1129-1134, (2002)

[4]

Reaven G.M., The role of insulin resistance in human disease, Diabetes, 37, pp. 1595-1607, (1988)

[5]

Reaven G.M., Why syndrome X? From Harold Himsworth to the insulin resistance syndrome, Cell Metab, 1, pp. 9-14, (2005)

[6]

Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults, JAMA, 285, pp. 2486-2497, (2001)

[7]

Pinkney J.H., Stehouwer C.D., Coppack S.W., Yudkin J.S., Endothelial dysfunction: Cause of the insulin resistance syndrome, Diabetes, 46, SUPPL. 52, (1997)

[8]

Clark M.G., Wallis M.G., Barrett E.J., Et al., Blood flow and muscle metabolism: A focus on insulin action, Am J Physiol Endocrinol Metab, 284, (2003)

[9]

Lerman A., Zeiher A.M., Endothelial function: Cardiac events, Circulation, 111, pp. 363-368, (2005)

[10]

Ganz P., Vita J.A., Testing endothelial vasomotor function: Nitric oxide, a multipotent molecule, Circulation, 108, pp. 2049-2053, (2003)

← 1 2 3 4 5 6 7 8 →